{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:07:55Z","timestamp":1789103275071,"version":"build-2803163510"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating small extracellular vesicle (sEV)-associated small nucleolar RNAs (snoRNAs) have emerged as candidate biomarkers because of their stability in biofluids. However, whether these molecular signals provide diagnostic information beyond established serum tumor markers remains uncertain. This study evaluated a four-snoRNA panel and investigated its incremental value when combined with carcinoembryonic antigen (CEA) and cytokeratin-19 fragment (CYFRA21-1) for NSCLC discrimination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center case-control study included 240 Untreated patients with pathologically or cytologically confirmed NSCLC and 205 healthy controls. A discovery microarray was performed using RNA isolated from the sEV-enriched fraction of three NSCLC samples and three controls. Four candidate snoRNAs (AC007956.1, AC093523.1, AL358875.1, and SNORA51) were subsequently quantified by quantitative reverse-transcription PCR using \u0394Ct values. Logistic regression models were developed for the four-snoRNA panel, the clinical marker model (CEA plus CYFRA21-1), and the combined six-marker model. Model performance was assessed using repeated stratified 10-fold cross-validation (20 repetitions), training-fold-derived thresholds, 2,000 stratified bootstrap resamples, calibration metrics, paired DeLong comparisons, subgroup analyses, and age\/sex-matched sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The discovery dataset contained 936 analyzable snoRNA probes. Although 134 probes showed nominal differential expression (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05), none remained significant after false-discovery-rate correction. NSCLC cases were older than controls (62.5 vs. 42.3 years; standardized mean difference, 1.73), whereas sex distributions were comparable. The four-snoRNA model achieved a cross-validated AUC of 0.924 (95% CI, 0.898-0.948), compared with 0.903 (95% CI, 0.874-0.931) for the CEA plus CYFRA21\u20131 model. The combined six-marker model showed the highest discrimination, with an AUC of 0.970 (95% CI, 0.955-0.983), sensitivity of 87.1%, specificity of 96.6%, calibration intercept of -0.018, calibration slope of 0.923, and Brier score of 0.064. Compared with the clinical model, the six-marker model increased AUC by 0.067 (95% CI, 0.043-0.092; paired DeLong\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). Model performance remained consistent in stage 0-II disease (AUC, 0.963; 95% CI, 0.940-0.980) and age\/sex-matched analyses (AUC, 0.964; 95% CI, 0.941-0.983). No snoRNA marker retained significant associations with clinical characteristics after multiple-testing correction.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A serum sEV-associated four-snoRNA panel showed incremental diagnostic value when combined with CEA and CYFRA21\u20131 in this exploratory NSCLC case-control study. The resulting six-marker model maintained discrimination during repeated internal cross-validation, including analyses restricted to early-stage disease and age\/sex-matched cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1881438","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:34:32Z","timestamp":1789101272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum small extracellular vesicle\u2013associated snoRNA panel adds diagnostic value to CEA and CYFRA21\u20131 for non-small cell lung cancer: an exploratory single-center study"],"prefix":"10.3389","volume":"16","author":[{"given":"Liguang","family":"Wang","sequence":"first","affiliation":[{"name":"Tumor Research and Treatment Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Blood Transfusion, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Affiliated Taian City Central Hospital of Qingdao University","place":["Taian, China"]},{"name":"Shandong Provincial Key Medical and Health Laboratory of Anti-drug Resistant Drug Research, Taian City Central Hospital","place":["Taian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Tumor Research and Treatment Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","article-title":"Reduced lung-cancer mortality with low-dose computed tomographic screening","volume":"365","author":"Aberle","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force recommendation statement","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209120","article-title":"Results of initial low-dose computed tomographic screening for lung cancer","volume":"368","author":"Church","year":"2013","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2012.03.005","article-title":"Small nucleolar RNAs in cancer","volume":"1826","author":"Mannoor","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3195","article-title":"Are snoRNAs and snoRNA host genes new players in cancer","volume":"12","author":"Williams","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-198","article-title":"Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer","volume":"9","author":"Liao","year":"2010","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.449","article-title":"Small nucleolar RNA 42 acts as an oncogene in lung tumorigenesis","volume":"31","author":"Mei","year":"2012","journal-title":"Oncogene"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-104","article-title":"Small nucleolar RNA signatures of lung tumor-initiating cells","volume":"13","author":"Mannoor","year":"2014","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29169","article-title":"Genome-wide small nucleolar RNA expression analysis of lung cancer by next-generation deep sequencing","volume":"136","author":"Gao","year":"2015","journal-title":"Int J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01570-y","article-title":"NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration","volume":"40","author":"Cui","year":"2021","journal-title":"Oncogene"},{"key":"B17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12935-024-03522-y","article-title":"Serum exosomal small nucleolar RNA (snoRNA) signatures as a predictive biomarker for benign and Malignant pulmonary nodules","volume":"24","author":"Cao","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.01.002","article-title":"Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer","volume":"80","author":"Okamura","year":"2013","journal-title":"Lung Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012799","article-title":"STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration","volume":"6","author":"Cohen","year":"2016","journal-title":"BMJ Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.3390\/cancers17233847","article-title":"Small nucleolar RNAs as emerging players in cancer biology and precision medicine","volume":"17","author":"Lorenzo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.21037\/jtd-2025-2010","article-title":"SCARNA20 influences the occurrence and development of lung cancer by inhibiting tumor cell proliferation, migration, and invasion","volume":"18","author":"Li","year":"2026","journal-title":"J Thorac Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6606076","article-title":"The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis","volume":"104","author":"Gee","year":"2011","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/biom15111625","article-title":"Function and mechanism of small nucleolar RNAs (snoRNAs) and their host genes (SNHGs) in Malignant tumors","volume":"15","author":"Yu","year":"2025","journal-title":"Biomolecules"},{"key":"B27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O'Brien","year":"2020","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"17436","DOI":"10.1038\/s41598-023-44218-z","article-title":"A novel sorting signal for RNA packaging into small extracellular vesicles","volume":"13","author":"Oka","year":"2023","journal-title":"Sci Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1724600819868234","article-title":"CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis","volume":"34","author":"Fu","year":"2019","journal-title":"Int J Biol Markers"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-210543","article-title":"Assessment of circulating biomarkers for detection of lung cancer in a high-risk cohort","volume":"36","author":"Borg","year":"2023","journal-title":"Cancer biomark"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1881438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:34:44Z","timestamp":1789101284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1881438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1881438"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1881438","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1881438"}}